Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (TLI), a not-for-profit organization that works at the nexus of science, ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular ...

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...